Amandine Crombé1, David Fadli2, Antoine Italiano3, Olivier Saut4, Xavier Buy2, Michèle Kind2. 1. Department of Radiology, Institut Bergonie, F-33000, Bordeaux, France; Modelisation in Oncology (MOnc) Team, INRIA Bordeaux-Sud-Ouest, CNRS UMR 5251, Université De Bordeaux, F-33405, Talence, France; University of Bordeaux, F-33000, Bordeaux, France. Electronic address: a.crombe@bordeaux.unicancer.fr. 2. Department of Radiology, Institut Bergonie, F-33000, Bordeaux, France. 3. University of Bordeaux, F-33000, Bordeaux, France; Department of Medical Oncology, Institut Bergonie, F-33000, Bordeaux, France. 4. Modelisation in Oncology (MOnc) Team, INRIA Bordeaux-Sud-Ouest, CNRS UMR 5251, Université De Bordeaux, F-33405, Talence, France.
Abstract
OBJECTIVES: Sarcomas are a model for intra- and inter-tumoral heterogeneities making them particularly suitable for radiomics analyses. Our purposes were to review the aims, methods and results of radiomics studies involving sarcomas METHODS: Pubmed and Web of Sciences databases were searched for radiomics or textural studies involving bone, soft-tissues and visceral sarcomas until June 2020. Two radiologists evaluated their objectives, results and quality of their methods, imaging pre-processing and machine-learning workflow helped by the items of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), Image Biomarker Standardization Initiative (IBSI) and 'Radiomics Quality Score' (RQS). Statistical analyses included inter-reader agreements, correlations between methodological assessments, scientometrics indices, and their changes over years, and between RQS, number of patients and models performance. RESULTS: Fifty-two studies were included involving: soft-tissue sarcomas (29/52, 55.8 %), bone sarcomas (15/52, 28.8 %), gynecological sarcomas (6/52, 11.5 %) and mixed sarcomas (2/52, 3.8 %), mostly imaged with MRI (36/52, 69.2 %), for a total of distinct patients. Median RQS was 4.5 (28.4 % of the maximum, range: -7 - 17). Performances of predictive models and number of patients negatively correlated (p = 0.027). None of the studies detailed all the items from the IBSI guidelines. There was a significant increase in studies' impact factors since the establishing of the RQS in 2017 (p = 0.038). CONCLUSION: Although showing promising results, further efforts are needed to make sarcoma radiomics studies reproducible with an acceptable level of evidence. A better knowledge of the RQS and IBSI reporting guidelines could improve the quality of sarcoma radiomics studies and accelerate clinical applications.
OBJECTIVES:Sarcomas are a model for intra- and inter-tumoral heterogeneities making them particularly suitable for radiomics analyses. Our purposes were to review the aims, methods and results of radiomics studies involving sarcomas METHODS: Pubmed and Web of Sciences databases were searched for radiomics or textural studies involving bone, soft-tissues and visceral sarcomas until June 2020. Two radiologists evaluated their objectives, results and quality of their methods, imaging pre-processing and machine-learning workflow helped by the items of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), Image Biomarker Standardization Initiative (IBSI) and 'Radiomics Quality Score' (RQS). Statistical analyses included inter-reader agreements, correlations between methodological assessments, scientometrics indices, and their changes over years, and between RQS, number of patients and models performance. RESULTS: Fifty-two studies were included involving: soft-tissue sarcomas (29/52, 55.8 %), bone sarcomas (15/52, 28.8 %), gynecological sarcomas (6/52, 11.5 %) and mixed sarcomas (2/52, 3.8 %), mostly imaged with MRI (36/52, 69.2 %), for a total of distinct patients. Median RQS was 4.5 (28.4 % of the maximum, range: -7 - 17). Performances of predictive models and number of patients negatively correlated (p = 0.027). None of the studies detailed all the items from the IBSI guidelines. There was a significant increase in studies' impact factors since the establishing of the RQS in 2017 (p = 0.038). CONCLUSION: Although showing promising results, further efforts are needed to make sarcoma radiomics studies reproducible with an acceptable level of evidence. A better knowledge of the RQS and IBSI reporting guidelines could improve the quality of sarcoma radiomics studies and accelerate clinical applications.